At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Extended Release Lamotriginedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Determination of Bioavailability and Clearance of Lamotrigine-XR by a Stable Isotope Technique
In Brief
A Phase 2 clinical trial evaluating Extended Release Lamotrigine for Epilepsy and 3 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
People over 65 years of ag break down (metabolize) drugs differently than younger adults. It is not known why this happens or how elderly people absorb or break down these drug differently. These difference may show that elderly individuals need lower doses of medications to avoid possible toxicity. We are interested in studying how yor body absorbs and breaks down your lamotrigine medication. This research may indicate that doses of lamotrigine should be lowered as people get older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Seizures, Bipolar Disorder, Bipolar Depression
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionJan 2011
TodayJul 2026
First PostedNov 11, 2008
Enrollment StartNov 1, 2008
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.6 years ago
Interventions
Extended Release Lamotriginedrug